Update shared on 14 Dec 2025
Fair value Increased 39%Analysts have trimmed their price target on Ambev to R$10.10 from R$10.20, reflecting weaker expected revenue growth and margins as they factor in the recent double digit contraction in Brazilian alcoholic beverage production.
Analyst Commentary
Bearish analysts are increasingly aligning around a more cautious stance on Ambev as they reassess earnings power and growth visibility in light of the sharp contraction in Brazilian alcoholic beverage production.
The latest reduction in the price target to R$10.10 signals growing concern that current market expectations may not fully incorporate the risk of a prolonged volume downturn and continued margin pressure.
Bearish Takeaways
- Bearish analysts view the double digit production decline as a sign that near term demand headwinds could persist, putting pressure on both top line growth and operating leverage.
- The reduced price target reflects increased execution risk around pricing, mix and cost control initiatives, which may not be sufficient to offset weaker volumes and rising input costs.
- There is rising concern that consensus earnings forecasts remain too optimistic, leading to potential downside to valuation multiples if growth expectations are revised lower.
- The ongoing contraction in industry production raises questions about the sustainability of Ambev's market share and profitability in its core Brazilian beer segment, reinforcing a cautious stance on the shares.
What's in the News
- The Board is scheduled to meet on December 9, 2025 to approve a dividend of R$0.4612 per share and interest on own capital based on an extraordinary balance sheet as of November 30, 2025 (Key Developments)
- The Board meeting is set for October 29, 2025 to review a potential share buyback program and the company’s disclosure and securities trading policy manual (Key Developments)
- Ambev announces a share repurchase program of up to 208 million common shares, or 4.89% of outstanding capital, with the option to cancel or hold shares in treasury, valid until April 29, 2027 (Key Developments)
- The Board of Directors formally authorizes the new share buyback plan on October 29, 2025, reinforcing capital return to shareholders (Key Developments)
Valuation Changes
- Fair Value Estimate increased from R$7.62 to R$10.60, implying a materially higher intrinsic value despite weaker operating assumptions.
- Discount Rate edged up from 17.32 percent to 18.16 percent, reflecting a slightly higher perceived risk profile or cost of capital.
- Revenue Growth was reduced sharply from 4.36 percent to 1.61 percent, signaling a significantly more cautious outlook on top line expansion.
- Net Profit Margin was trimmed modestly from 15.98 percent to 15.57 percent, indicating slightly lower expected profitability on future sales.
- Future P/E was revised higher from 11.35x to 17.98x, suggesting that more of the valuation is now driven by multiple expansion rather than earnings growth.
Have other thoughts on Ambev?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
